Ocular Delivery of Proteins and Peptides
Biotechnology is steadily becoming an important component of the pharmaceutical industry. The numbers of protein and peptide ocular based drugs being developed have increased. The technique to formulate peptide or protein ocular drugs is very different from formulating conventional small molecule drugs. Additionally, the delivery of a peptide or protein-based drugs is particularly challenging due to the issues of protein instability. This chapter discusses the development of proteins and peptides for ocular delivery with an emphasis on their specific considerations and challenges, and a role of specific proteins such as alpha crystallins and thymosin β4 in ocular drug delivery. Possible routes of protein ocular drug delivery are also discussed.
KeywordsOcular peptides delivery Proteins delivery Peptides delivery Route of delivery
- Ambati J, Gragoudas ES, Miller JW et al (2000) Transcleral delivery of bioactive protein to the choroid and retina. Invest Opthamol Vis Sci. 41(5):1186–1191Google Scholar
- Nguyen QD, Shah SM, Browning DJ et al (2009) A phase 1 study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Opthamol. 116(11):2141–2148Google Scholar
- Zhou XH, Po LW (1991) Peptide and protein drugs: therapeutic applications, absorption, and parenteral administration. Int J Pharm 75:97–115Google Scholar
Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.